A Phase 1 Combined Single and Multiple Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2018
At a glance
- Drugs Fezolinetant (Primary)
- Indications Hot flashes; Polycystic ovary syndrome; Uterine leiomyoma; Weight gain
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 05 Jun 2018 Status changed from active, no longer recruiting to completed.
- 11 May 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2018 Status changed from not yet recruiting to recruiting.